UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 55

Sortiert nach

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma

Annals of oncology, 2018-03, Vol.29 (3), p.700-706

2018

Volltextzugriff (PDF)

Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407

Annals of oncology, 2019-10, Vol.30, p.v917-v918

2019

Volltextzugriff (PDF)

Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders

European journal of cancer (1990), 2017-02, Vol.72, p.S185-S185

2017

Volltextzugriff (PDF)

1544P Pre-treatment CT radiomics predicts survival in chemo-immunotherapy-treated small cell lung cancer

Annals of oncology, 2022-09, Vol.33, p.S1253

2022

Volltextzugriff (PDF)

Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study

Annals of oncology, 2020-08, Vol.31 (8), p.1056-1064

2020

Volltextzugriff (PDF)

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

Annals of oncology, 2019-05, Vol.30 (5), p.839-844

2019

Volltextzugriff (PDF)

10LBA Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer

European journal of cancer (1990), 2014-11, Vol.50, p.199-199

2014

Volltextzugriff (PDF)

1317P Renal toxicity in black patients with non-squamous non-small cell lung cancer treated with combination platinum-pemetrexed-pembrolizumab therapy

Annals of oncology, 2021-09, Vol.32, p.S1013-S1013

2021

Volltextzugriff (PDF)

Differential Role of Soy Isoflavones in Radiotherapy of Lung Cancer: Augmenting Tumor Response and Protecting Normal Tissue

International journal of radiation oncology, biology, physics, 2011, Vol.81 (2), p.S736-S736

2011

Volltextzugriff (PDF)

Salvage Fast Neutron Radiotherapy for Treatment of Refractory Non-small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2010, Vol.78 (3), p.S504-S505

2010

Volltextzugriff (PDF)

Fast Neutron Radiotherapy for Advanced Stage Non-small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2010, Vol.78 (3), p.S509-S509

2010

Volltextzugriff (PDF)

1388P Real-world prognostic value of RET fusions in advanced non-small cell lung cancer (aNSCLC)

Annals of oncology, 2023-10, Vol.34, p.S795-S796

2023

Volltextzugriff (PDF)

The Selective Personalized Radioimmunotherapy for Locally Advanced NSCLC Trial (SPRINT): Patient-Reported Outcomes

International journal of radiation oncology, biology, physics, 2024-10, Vol.120 (2), p.S59-S59

2024

Volltextzugriff (PDF)

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma

Annals of oncology, 2018-10, Vol.29 (10), p.2143-2143

2018

Volltextzugriff (PDF)

Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors

European journal of cancer (1990), 2022-10, Vol.174, p.S6-S7

2022

Volltextzugriff (PDF)

The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial (SPRINT)

International journal of radiation oncology, biology, physics, 2022-11, Vol.114 (3), p.S31

2022

Volltextzugriff (PDF)

1301P Blood first assay screening trial (BFAST) in patients (pts) with 1L NSCLC: ALK+ cohort updated biomarker analyses

Annals of oncology, 2020-09, Vol.31, p.S841-S841

2020

Volltextzugriff (PDF)

EP10.01-03 A Phase 1/2 Study of REGN5093-M114, a METxMET Antibody-Drug Conjugate, in Patients with MET-Overexpressing NSCLC

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S602-S603

2023

Volltextzugriff (PDF)

1549TiP DeLLphi-303: Phase Ib first-line combination study of tarlatamab, a DLL3-targeting half-life extended bispecific T-cell engager (HLE BiTE®), with carboplatin, etoposide, and PD-L1 inhibition in extensive stage small cell lung cancer (ES-SCLC)

Annals of oncology, 2022-09, Vol.33, p.S1255

2022

Volltextzugriff (PDF)

1361P Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A

Annals of oncology, 2023-10, Vol.34, p.S782-S783

2023

Volltextzugriff (PDF)

RORγ agonist LYC-55716 in combination with pembrolizumab to treat metastatic non-small cell lung cancer: An open-label, multicenter phase Ib trial

Annals of oncology, 2018-10, Vol.29, p.viii417-viii417

2018

Volltextzugriff (PDF)

1271P 4-year survival in randomised phase II (POPLAR) and phase III (OAK) studies of atezolizumab (atezo) vs docetaxel (doc) in pre-treated NSCLC

Annals of oncology, 2020-09, Vol.31, p.S821-S822

2020

Volltextzugriff (PDF)

1302P Lorlatinib in patients with ALK+ NSCLC treated beyond initial disease progression

Annals of oncology, 2020-09, Vol.31, p.S842-S842

2020

Volltextzugriff (PDF)

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

Annals of oncology, 2024-09, Vol.35 (9), p.805-816

2024

Volltextzugriff (PDF)

IM01.01 4-Year Survival in Randomised Phase II (POPLAR) and Phase III (OAK) Studies of Atezolizumab vs. Docetaxel in 2L+ NSCLC

Journal of thoracic oncology, 2021-01, Vol.16 (1), p.S15-S15

2021

Volltextzugriff (PDF)

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(54)

Publikationsform

Artikel
(55)

Sprache

Englisch
(55)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Hematology, Oncology And Palliative Medicine
(6)
Humans
(5)
Life Sciences & Biomedicine
(5)
Oncology
(5)
Science & Technology
(5)
Adult
(3)
Aged
(3)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(3)
Erbb Receptors - Genetics
(3)
Female
(3)
Lung Neoplasms - Drug Therapy
(3)
Male
(3)
Middle Aged
(3)
Radiology
(3)
Carcinoma, Non-Small-Cell Lung - Genetics
(2)
Ctdna
(2)
Egfr
(2)
Lung Neoplasms - Genetics
(2)
Nsclc
(2)
Protein Kinase Inhibitors - Therapeutic Use
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

1 weiteren anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma

Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407

Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders

1544P Pre-treatment CT radiomics predicts survival in chemo-immunotherapy-treated small cell lung cancer

Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

10LBA Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer

1317P Renal toxicity in black patients with non-squamous non-small cell lung cancer treated with combination platinum-pemetrexed-pembrolizumab therapy

Differential Role of Soy Isoflavones in Radiotherapy of Lung Cancer: Augmenting Tumor Response and Protecting Normal Tissue

Salvage Fast Neutron Radiotherapy for Treatment of Refractory Non-small Cell Lung Cancer

Fast Neutron Radiotherapy for Advanced Stage Non-small Cell Lung Cancer

1388P Real-world prognostic value of RET fusions in advanced non-small cell lung cancer (aNSCLC)

The Selective Personalized Radioimmunotherapy for Locally Advanced NSCLC Trial (SPRINT): Patient-Reported Outcomes

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma

Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors

The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial (SPRINT)

1301P Blood first assay screening trial (BFAST) in patients (pts) with 1L NSCLC: ALK+ cohort updated biomarker analyses

EP10.01-03 A Phase 1/2 Study of REGN5093-M114, a METxMET Antibody-Drug Conjugate, in Patients with MET-Overexpressing NSCLC

1549TiP DeLLphi-303: Phase Ib first-line combination study of tarlatamab, a DLL3-targeting half-life extended bispecific T-cell engager (HLE BiTE®), with carboplatin, etoposide, and PD-L1 inhibition in extensive stage small cell lung cancer (ES-SCLC)

1361P Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A

RORγ agonist LYC-55716 in combination with pembrolizumab to treat metastatic non-small cell lung cancer: An open-label, multicenter phase Ib trial

1271P 4-year survival in randomised phase II (POPLAR) and phase III (OAK) studies of atezolizumab (atezo) vs docetaxel (doc) in pre-treated NSCLC

1302P Lorlatinib in patients with ALK+ NSCLC treated beyond initial disease progression

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

IM01.01 4-Year Survival in Randomised Phase II (POPLAR) and Phase III (OAK) Studies of Atezolizumab vs. Docetaxel in 2L+ NSCLC

Suchergebnisse filtern